Coeptis Therapeutics (COEP) News Today $0.26 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period June 20, 2024 | prnewswire.comCoeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingMay 30, 2024 | prnewswire.comCoeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingMay 13, 2024 | msn.comCOEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024May 8, 2024 | prnewswire.comCoeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024May 2, 2024 | prnewswire.comCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingApril 24, 2024 | finance.yahoo.comDeverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid LeukemiaApril 2, 2024 | prnewswire.comCoeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardApril 1, 2024 | investorplace.comCOEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023February 28, 2024 | investing.comCoeptis expands license for CAR technology to autoimmune diseasesFebruary 26, 2024 | finance.yahoo.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 26, 2024 | prnewswire.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 17, 2024 | morningstar.comCoeptis Therapeutics Holdings Inc Ordinary Shares COEPFebruary 7, 2024 | finance.yahoo.comCoeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsFebruary 2, 2024 | msn.comCoeptis Therapeutics Risks Nasdaq Delisting Over Bid PriceJanuary 29, 2024 | insidertrades.comThese are the 4 hottest stocks insiders bought in JanuaryJanuary 4, 2024 | finance.yahoo.comCoeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024December 9, 2023 | benzinga.comCoeptis Therapeutics Stock (NASDAQ:COEP) Insider TradesDecember 4, 2023 | finance.yahoo.comCoeptis Therapeutics to Present at the Emerging Growth ConferenceNovember 15, 2023 | markets.businessinsider.comBuy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing AssetsOctober 31, 2023 | finance.yahoo.comCoeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023October 24, 2023 | msn.comCoeptis Therapeutics to raise $2M in a private placementOctober 24, 2023 | finance.yahoo.comCoeptis Therapeutics Announces $2 Million Private PlacementOctober 11, 2023 | bizjournals.comLocal pharma firm widens technology deal with the University of PittsburghOctober 11, 2023 | markets.businessinsider.comCoeptis Expands License Agreement With University Of Pittsburgh To Include SNAP-CAR PlatformOctober 9, 2023 | finance.yahoo.comCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesOctober 4, 2023 | finance.yahoo.comCoeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingSeptember 27, 2023 | finance.yahoo.comCoeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaSeptember 20, 2023 | msn.comSeattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapiesSeptember 14, 2023 | finance.yahoo.comCoeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionSeptember 11, 2023 | finance.yahoo.comCoeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentSeptember 5, 2023 | bizjournals.comCoeptis appoints Colleen Delaney as chief scientific and medical officerAugust 30, 2023 | finance.yahoo.comCoeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerAugust 17, 2023 | baystreet.caCoeptics Flat on Deverra DealAugust 17, 2023 | finance.yahoo.comCoeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsAugust 1, 2023 | finance.yahoo.comCoeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticJuly 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Mirati Therapeutics (MRTX), Clearside Biomedical (CLSD)June 16, 2023 | finance.yahoo.comCoeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingJune 14, 2023 | benzinga.comCoeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten OfferingJune 14, 2023 | finance.yahoo.comCoeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingJune 12, 2023 | markets.businessinsider.comEF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)June 9, 2023 | bizjournals.comCoeptis Therapeutics to join Nasdaq Capital Market next MondayJune 9, 2023 | finance.yahoo.comCoeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital MarketMay 30, 2023 | benzinga.comCoeptis Therapeutics Shares Rally 67% In May, Clinical Interests And Planned Acquisitions Attract The Interest ($COEP)May 17, 2023 | finance.yahoo.comCoeptis Therapeutics Appoints Brian Cogley as Chief Financial OfficerMay 11, 2023 | markets.businessinsider.comJonesTrading Keeps Their Buy Rating on Coeptis Therapeutics Holdings (COEP)May 10, 2023 | finance.yahoo.comCoeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature CommunicationsApril 19, 2023 | msn.comJonesTrading Initiates Coverage of Coeptis Therapeutics Holdings (COEP) with Buy RecommendationApril 19, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For April 19, 2023April 18, 2023 | msn.comCoeptis Rises on Key Assets Acquisition from DeverraApril 18, 2023 | bizjournals.comCoeptis Therapeutics to acquire cell therapies from Deverra Therapeutics Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. COEP Media Mentions By Week COEP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COEP News Sentiment▼0.430.61▲Average Medical News Sentiment COEP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COEP Articles This Week▼20▲COEP Articles Average Week Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BM Technologies News Dyadic International News Aligos Therapeutics News Curis News IN8bio News Cyclo Therapeutics News Achilles Therapeutics News Quince Therapeutics News NKGen Biotech News MiNK Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COEP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
